Copy to clipboard 
Enovis reported 1Q26 orthopedic sales of $317.1 million, up 10.8% compared to the first quarter of 2025. Excluding the impact of currency translation, the company grew 5.5% for the quarter.
The first quarter brought a dynamic environment in which Enovis was able to execute and expand its market presence. Most notably, its Nebula hip continues to be a growth driver, especially in competitive accounts. While still early in the launch cycle, Nebula is unlocking a meaningful segment of the U.S. hip market for the company.
“I mean that’s a market that we were locked out of,” said Enovis CEO Damien McDonald. “Someone reported the other day that something like 40% of their business now is in triple taper and we’re not anywhere near that sort of penetration yet. About half of our knee surgeons don’t use our hip because we haven’t had an offering. So we’ve got a funnel of opportunity to convert those people over to our hip in a market that’s been largely dominated by J&J and Zimmer Biomet.”
The company’s augmented reverse glenoid shoulder continues to gain traction and drove double-digit growth, supported by the continuing rollout of ARVIS for shoulder surgery. ARVIS also completed its first OUS shoulder case in South Africa.
Outside the United States, markets experienced volatility in the early part of the year. However, Enovis expects those markets to recover to normal levels throughout the year.
The company reaffirmed its 2026 guidance of total revenue growth between 3% and 5%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $277.0 | $248.8 | $28.3 | 11.4% |
| Knees | $64.1 | $58.7 | $5.4 | 9.2% |
| Hips | $90.4 | $83.0 | $7.4 | 8.9% |
| Extremities | $122.6 | $107.1 | $15.5 | 14.5% |
| Trauma | $30.1 | $27.8 | $2.4 | 8.5% |
| Other | $10.0 | $9.7 | $0.3 | 2.6% |
| Total | $317.1 | $286.3 | $30.9 | 10.8% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $149.2 | $137.9 | $11.3 | 8.2% |
| OUS | $167.9 | $148.4 | $19.6 | 13.2% |
| EMEA | $126.8 | $112.8 | $14.0 | 12.4% |
| APAC | $23.7 | $20.8 | $2.9 | 14% |
| ROW | $17.5 | $14.8 | $2.6 | 17.7% |
| Total | $317.1 | $286.3 | $30.9 | 10.8% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $516.3 | |
| Cost of Sales | $218.4 | 42.3% |
| Selling and Admin | $255.7 | 49.5% |
| R&D | $23.4 | 10.7% |
| Other | $90.8 | 17.6% |
| Net Earnings | ($72.0) | (13.9%) |
Enovis reported 1Q26 orthopedic sales of $317.1 million, up 10.8% compared to the first quarter of 2025. Excluding the impact of currency translation, the company grew 5.5% for the quarter.
The first quarter brought a dynamic environment in which Enovis was able to execute and expand its market presence. Most notably, its Nebula hip...
Enovis reported 1Q26 orthopedic sales of $317.1 million, up 10.8% compared to the first quarter of 2025. Excluding the impact of currency translation, the company grew 5.5% for the quarter.
The first quarter brought a dynamic environment in which Enovis was able to execute and expand its market presence. Most notably, its Nebula hip continues to be a growth driver, especially in competitive accounts. While still early in the launch cycle, Nebula is unlocking a meaningful segment of the U.S. hip market for the company.
“I mean that’s a market that we were locked out of,” said Enovis CEO Damien McDonald. “Someone reported the other day that something like 40% of their business now is in triple taper and we’re not anywhere near that sort of penetration yet. About half of our knee surgeons don’t use our hip because we haven’t had an offering. So we’ve got a funnel of opportunity to convert those people over to our hip in a market that’s been largely dominated by J&J and Zimmer Biomet.”
The company’s augmented reverse glenoid shoulder continues to gain traction and drove double-digit growth, supported by the continuing rollout of ARVIS for shoulder surgery. ARVIS also completed its first OUS shoulder case in South Africa.
Outside the United States, markets experienced volatility in the early part of the year. However, Enovis expects those markets to recover to normal levels throughout the year.
The company reaffirmed its 2026 guidance of total revenue growth between 3% and 5%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $277.0 | $248.8 | $28.3 | 11.4% |
| Knees | $64.1 | $58.7 | $5.4 | 9.2% |
| Hips | $90.4 | $83.0 | $7.4 | 8.9% |
| Extremities | $122.6 | $107.1 | $15.5 | 14.5% |
| Trauma | $30.1 | $27.8 | $2.4 | 8.5% |
| Other | $10.0 | $9.7 | $0.3 | 2.6% |
| Total | $317.1 | $286.3 | $30.9 | 10.8% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $149.2 | $137.9 | $11.3 | 8.2% |
| OUS | $167.9 | $148.4 | $19.6 | 13.2% |
| EMEA | $126.8 | $112.8 | $14.0 | 12.4% |
| APAC | $23.7 | $20.8 | $2.9 | 14% |
| ROW | $17.5 | $14.8 | $2.6 | 17.7% |
| Total | $317.1 | $286.3 | $30.9 | 10.8% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $516.3 | |
| Cost of Sales | $218.4 | 42.3% |
| Selling and Admin | $255.7 | 49.5% |
| R&D | $23.4 | 10.7% |
| Other | $90.8 | 17.6% |
| Net Earnings | ($72.0) | (13.9%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
